アブストラクト
| Title | 免疫チェックポイント阻害薬の副作用 〜神経領域〜 |
|---|---|
| Subtitle | 特集「ここまできたがん免疫療法」 |
| Authors | 市川弥生子 |
| Authors (kana) | |
| Organization | 杏林大学医学部脳神経内科学教室 |
| Journal | 杏林医学会雑誌 |
| Volume | 51 |
| Number | 3 |
| Page | 239-245 |
| Year/Month | 2020 / 9 |
| Article | 報告 |
| Publisher | 杏林医学会 |
| Abstract | 「要旨」免疫チェックポイント阻害薬の神経領域における副作用は, 頻度は低いが, 病変が中枢神経から末梢神経, 神経筋接合部, 骨格筋にまでおよび, 多彩であることが特徴である. がんの直接浸潤や傍腫瘍性神経症候群, 過去のがん治療における副作用の影響も考慮しなければならず, 免疫チェックポイント阻害薬を起因とする有害事象の診断は容易ではない. 免疫チェックポイント阻害薬の免疫関連有害事象には, 自己免疫性脳炎, 重症筋無力症, 筋炎, Guillain-Barre症候群のような重症化しやすい疾患が含まれる. これらの疾患が, 通常の神経内科臨床とは異なる病像をとりうること, 急速に進行し, 重篤な経過をとることに注意が必要である. 神経系の免疫関連有害事象に, ステロイドを主体とした免疫抑制治療は有効であり, 迅速な診断と, 適切な治療が求められる. がん専門医と脳神経内科医とで診療にあたる必要がある. |
| Practice | 臨床医学：一般 |
| Keywords | 免疫チェックポイント阻害薬, 免疫関連有害事象, 重症筋無力症, 筋炎, Guillain-Barre症候群 |
- 全文ダウンロード： 従量制、基本料金制の方共に770円(税込) です。
参考文献
- 1) Cuzzubbo S., Javeri F., Tissier M., Roumi A., Barlog C., Doridam J., Lebbe C., Belin C., Ursu R., Carpentier A. F.: Neurological adverse events associated with immune checkpoint inhibitors : Review of the literature. European Journal of Cancer(Oxford, England : 1990) 73 : 1-8, 2017.
- 2) Haanen, J. B. a. G., Carbonnel F., Robert C., Kerr K. M., Peters S., Larkin J., Jordan K.: Management of toxicities from immunotherapy : ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology : Official Journal of the European Society for Medical Oncology 28 : iv119-iv142, 2017.
- 3) Larkin James, Chmielowski Bartosz, Lao Christopher D., Hodi F. Stephen, Sharfman William, Weber Jeffrey, Suijkerbuijk Karijn P. M., Azevedo Sergio, Li Hewei, Reshef Daniel, Avila Alexandre, Reardon David A.: Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis. The Oncologist 22 : 709-718, 2017.
- 4) 鈴木重明 : 免疫チェックポイント阻害薬による神経・筋障害. BRAIN and NERVE-神経研究の進歩 70 : 461-466, 2018.
- 5) 鈴木重明 : 【免疫チェックポイント阻害剤の副作用と対策】神経・筋障害. 癌と化学療法 45 : 1036-1040, 2018.
残りの17件を表示する
- 6) Astaras Christophoros, de Micheli Rita, Moura Bianca, Hundsberger Thomas, Hottinger Andreas F.: Neurological Adverse Events Associated with Immune Checkpoint Inhibitors : Diagnosis and Management. Current Neurology and Neuroscience Reports 18 : 3, 2018.
- 7) Williams Tanya J., Benavides David R., Patrice Kelly-Ann, Dalmau Josep O., de Avila, Alexandre Leon Ribeiro, Le Dung T., Lipson Evan J., Probasco John C., Mowry Ellen M.: Association of Autoimmune Encephalitis With Combined Immune Checkpoint Inhibitor Treatment for Metastatic Cancer. JAMA neurology 73 : 928-933, 2016.
- 8) Kimura Toshihiro, Fukushima Satoshi, Miyashita Azusa, Aoi Jun, Jinnin Masatoshi, Kosaka Takayuki, Ando Yukio, Matsukawa Masakazu, Inoue Hiroyuki, Kiyotani Kazuma, Park Jae-Hyun, Nakamura Yusuke, Ihn Hironobu : Myasthenic crisis and polymyositis induced by one dose of nivolumab. Cancer Science 107 : 1055-1058, 2016.
- 9) Suzuki Shigeaki, Ishikawa Nobuhisa, Konoeda Fumie, Seki Nobuhiko, Fukushima Satoshi, Takahashi Kikuko, Uhara Hisashi, Hasegawa Yoshikazu, Inomata Shinichiro, Otani Yasushi, Yokota Kenji, Hirose Takashi, Tanaka Ryo, Suzuki Norihiro, Matsui Makoto : Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan. Neurology 89 : 1127-1134, 2017.
- 10) 鈴木重明 : 【「重症筋無力症Up to date」】免疫チェックポイント阻害薬による重症筋無力症. 臨床神経生理学 46 : 101-104, 2018.
- 11) 鈴木重明 : 重症筋無力症と筋炎(PD-1ミオパチー). 癌と化学療法 47 : 219-223, 2020.
- 12) Seki Morinobu, Uruha Akinori, Ohnuki Yuko, Kamada Sachiko, Noda Tomoko, Onda Asako, Ohira Masayuki, Isami Aiko, Hiramatsu Sumie, Hibino Makoto, Nakane Shunya, Noda Seiya, Yutani Sachiko, Hanazono Akira, Yaguchi Hiroshi, Takao Masaki, Shiina Takashi, Katsuno Masahisa, Nakahara Jin, Matsubara Shiro, Nishino Ichizo, Suzuki Shigeaki : Inflammatory myopathy associated with PD-1 inhibitors. Journal of Autoimmunity 100 : 105-113, 2019.
- 13) Kao Justin C., Liao Bing, Markovic Svetomir N., Klein Christopher J., Naddaf Elie, Staff Nathan P., Liewluck Teerin, Hammack Julie E., Sandroni Paola, Finnes Heidi, Mauermann Michelle L.: Neurological Complications Associated With Anti-Programmed Death 1(PD-1) Antibodies. JAMA neurology 74 : 1216-1222, 2017.
- 14) Hottinger Andreas F.: Neurologic complications of immune checkpoint inhibitors. Current Opinion in Neurology 29 : 806-812, 2016.
- 15) de Maleissye Marie-Florence, Nicolas Guillaume, Saiag Philippe : Pembrolizumab-Induced Demyelinating Polyradiculoneuropathy. The New England Journal of Medicine 375 : 296-297, 2016.
- 16) Wilgenhof S., Neyns B.: Anti-CTLA-4 antibody-induced Guillain-Barre syndrome in a melanoma patient. Annals of Oncology : Official Journal of the European Society for Medical Oncology 22 : 991-993, 2011.
- 17) Zimmer Lisa, Goldinger Simone M., Hofmann Lars, Loquai Carmen, Ugurel Selma, Thomas Ioannis, Schmidgen Maria I., Gutzmer Ralf, Utikal Jochen S., Goppner Daniela, Hassel Jessica C., Meier Friedegund, Tietze Julia K., Forschner Andrea, Weishaupt Carsten, Leverkus Martin, Wahl Renate, Dietrich Ursula, Garbe Claus, Kirchberger Michael C., Eigentler Thomas, Berking Carola, Gesierich Anja, Krackhardt Angela M., Schadendorf Dirk, Schuler Gerold, Dummer Reinhard, Heinzerling Lucie M.: Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. European Journal of Cancer 60 : 210-225, 2016.
- 18) Liao Bing, Shroff Sheetal, Kamiya-Matsuoka Carlos, Tummala Sudhakar : Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma. Neuro-Oncology 16 : 589-593, 2014.
- 19) Patel Akshita S., Snook Riley J., Sehdev Amikar : Chronic inflammatory demyelinating polyradiculoneuropathy secondary to immune checkpoint inhibitors in melanoma patients. Discovery Medicine 28 : 107-111, 2019.
- 20) Chiba A., Kusunoki S., Obata H., Machinami R., Kanazawa I.: Serum anti-GQ1b IgG antibody is associated with ophthalmoplegia in Miller Fisher syndrome and Guillain-Barre syndrome : clinical and immunohistochemical studies. Neurology 43 : 1911-1917, 1993.
- 21) Brahmer Julie R., Lacchetti Christina, Schneider Bryan J., Atkins Michael B., Brassil Kelly J., Caterino Jeffrey M., Chau Ian, Ernstoff Marc S., Gardner Jennifer M., Ginex Pamela, Hallmeyer Sigrun, Holter Chakrabarty Jennifer, Leighl Natasha B., Mammen Jennifer S., McDermott David F., Naing Aung, Nastoupil Loretta J., Phillips Tanyanika, Porter Laura D., Puzanov Igor, Reichner Cristina A., Santomasso Bianca D., Seigel Carole, Spira Alexander, Suarez-Almazor Maria E., Wang Yinghong, Weber Jeffrey S., Wolchok Jedd D., Thompson John A.: Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy : American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 36 : 1714-1768, 2018.
- 22) Dyck P. James B., Tracy Jennifer A.: History, Diagnosis, and Management of Chronic Inflammatory Demyelinating Polyradiculoneuropathy. Mayo Clinic Proceedings 93 : 777-793, 2018.
